Cell Cycle News and Research

RSS

Cell-cycle arrest biomarkers validated for acute kidney injury

Saeed A. Jortani, Ph.D., associate clinical professor in the University of Louisville's Department of Pathology and Laboratory Medicine, headed up one of three labs in the United States involved in determining two new markers for acute kidney injury (AKI). The research group's paper, "Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication," was posted online Feb. 25 by the American Journal of Respiratory and Critical Care Medicine.

5 Mar 2014

Protein that controls Drosophila nervous system may play role in reversing brain injuries in human

A protein that controls the metamorphosis of the common fruit fly could someday play a role in reversing brain injuries, said Duke University researchers.

28 Feb 2014

Research reveals very unique evolutionary innovations in primate brain

New research by UC Santa Barbara's Kenneth S. Kosik, Harriman Professor of Neuroscience, reveals some very unique evolutionary innovations in the primate brain.

28 Feb 2014

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies.

19 Feb 2014

Researchers discover protein for treatment of anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.

19 Feb 2014

NUS researchers discover promising treatment for anaplastic thyroid carcinoma

Anaplastic thyroid carcinoma is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.

18 Feb 2014

Scientists explain why women with dense breast tissue at greater risk of developing breast cancer

Scientists from The University of Manchester working with IBM Research have identified a key biological mechanism that for the first time explains why women with dense breast tissue are at greater risk of developing breast cancer.

12 Feb 2014

TGen study reveals genetic origins of breast cancer that spreads to brain

The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first-of-its-kind study published in the scientific journal PLOS ONE.

11 Feb 2014

Splicing findings offer lung cancer clues

Researchers from Spain have identified several new splicing events regulated by the oncogenic splicing factor SRSF1 in lung cancer, suggesting that their dysregulation is involved in the pathogenesis of the disease.

4 Feb 2014

Bladder, lung cancers are marked by shared differences in genetics that control cell cycle

A University of Colorado Cancer Center study published in the journal PLoS ONE shows that bladder and lung cancers are marked by shared differences in the genetics that control the cell cycle.

30 Jan 2014

Phasefocus reports on new ptychography paper published in Nature Scientific Reports

Cell imaging often relies on synthetic or genetic fluorescent labels, to provide contrast which can be far from ideal for imaging cells in their in vivo state. We report on the biological application of a label-free, high contrast microscopy technique known as ptychography, in which the image producing step is transferred from the microscope lens to a high-speed phase retrieval algorithm.

From Phase Focus Limited 28 Jan 2014

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.

28 Jan 2014

South Korean lung SCC genetic secrets revealed

Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say.

27 Jan 2014

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Mesothelioma is a very aggressive cancer associated with asbestos exposure, which is usually diagnosed in an advanced stage. So far no therapeutic strategy has proven effective against this deadly cancer and the prognosis remains very poor with only few exceptions.

20 Jan 2014

Researchers managed to replicate human pancreatic beta cells in mouse model

Klaus Kaestner, PhD, professor of Genetics and postdoctoral fellow Dana Avrahami, PhD, from the Perelman School of Medicine, University of Pennsylvania, published a study this week in the Journal of Clinical Investigation, with colleague Benjamin Glaser, MD, from the Hadassah-Hebrew University Medical Center, Jerusalem, and colleagues. In this study, they were able to replicate human pancreatic beta cells - the cells in our body that produce the critical hormone insulin - in a mouse model in which donor cells were transplanted. The newly replicated cells retained features of mature beta cells and showed a physiological response to glucose.

17 Jan 2014

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

IDIBELL researchers explain the regulator mechanisms of mitosis

Researchers at the Cell Cycle Research Group of the Bellvitge Institute of Biomedical Research (IDIBELL) led by Ethel Queralt have reported in the journal PLoS Genetics an article which delve into the regulator mechanisms of mitosis, a key stage of the cell-cycle for the correct transmision of genetic information from parents to sons.

12 Dec 2013

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

Researchers from the Laboratory of Cancer Metabolism (LCM) led by George Thomas at the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Division of Hematology/ Oncology, University of Cincinnati, have shown that loss of either one of two tumor suppressors, ribosomal proteins RPL5 or RPL11, fail to induce cell-cycle arrest, but prevent the proliferation of cells as they have a reduced capacity to synthesize proteins.

12 Dec 2013

Two tumor-suppressing genes could play vital role in controlling obesity, cancer, diabetes

The function of two tumor-suppressing genes could play a vital role in helping to control obesity and other diseases such as diabetes, heart disease and cancer, according to researchers in Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.

12 Dec 2013

Cell Cycle News and Research

Cell-cycle arrest biomarkers validated for acute kidney injury

Protein that controls Drosophila nervous system may play role in reversing brain injuries in human

Research reveals very unique evolutionary innovations in primate brain

Experimental drug dinaciclib may improve myeloid leukemia, myeloma therapies

Researchers discover protein for treatment of anaplastic thyroid carcinoma

NUS researchers discover promising treatment for anaplastic thyroid carcinoma

Scientists explain why women with dense breast tissue at greater risk of developing breast cancer

TGen study reveals genetic origins of breast cancer that spreads to brain

Splicing findings offer lung cancer clues

Bladder, lung cancers are marked by shared differences in genetics that control cell cycle

Phasefocus reports on new ptychography paper published in Nature Scientific Reports

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

South Korean lung SCC genetic secrets revealed

Studies aim to address urgent need to identify possible new methods for mesothelioma treatment

Researchers managed to replicate human pancreatic beta cells in mouse model

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Study could lead towards a personalised medicine for chemoresistant lymphomata

IDIBELL researchers explain the regulator mechanisms of mitosis

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

Two tumor-suppressing genes could play vital role in controlling obesity, cancer, diabetes

Optimizing cell line development for recombinant proteins and monoclonal antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics